BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35124261)

  • 1. Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers.
    Benning L; Morath C; Bartenschlager M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schaier M; Klein K; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Speer C
    Clin Microbiol Infect; 2022 Jul; 28(7):1024.e7-1024.e12. PubMed ID: 35124261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.
    Benning L; Klein K; Morath C; Bartenschlager M; Kim H; Buylaert M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Schaier M; Speer C
    Front Immunol; 2022; 13():840136. PubMed ID: 35309320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.
    Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
    Microbiol Spectr; 2021 Dec; 9(3):e0056121. PubMed ID: 34851162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
    Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
    Front Immunol; 2022; 13():909910. PubMed ID: 35784321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
    Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2.
    Chau NVV; Nguyet LA; Dung NT; Quang VM; Truong NT; Toan LM; Hung LM; Man DNH; Khoa DB; Phong NT; Ngoc NM; Thao HP; Ty DTB; Thanh PB; Ny NTH; Thanh LK; Thuy CT; Anh NT; Hong NTT; Nhu LNT; Yen LM; Thwaites G; Thanh TT; Tan LV;
    Am J Trop Med Hyg; 2023 Jan; 108(1):137-144. PubMed ID: 36450229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
    Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C
    Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
    Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
    Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2.
    Speer C; Göth D; Benning L; Buylaert M; Schaier M; Grenz J; Nusshag C; Kälble F; Kreysing M; Reichel P; Töllner M; Hidmark A; Ponath G; Schnitzler P; Zeier M; Süsal C; Morath C; Klein K
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1073-1082. PubMed ID: 34031181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium.
    Calcoen B; Callewaert N; Vandenbulcke A; Kerstens W; Imbrechts M; Vercruysse T; Dallmeier K; Van Weyenbergh J; Maes P; Bossuyt X; Zapf D; Dieckmann K; Callebaut K; Thibaut HJ; Vanhoorelbeke K; De Meyer SF; Maes W; Geukens N
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination.
    Dobaño C; Ramírez-Morros A; Alonso S; Ruiz-Olalla G; Rubio R; Vidal M; Prados de la Torre E; Jairoce C; Mitchell RA; Barrios D; Jiménez A; Rodrigo Melero N; Carolis C; Izquierdo L; Zanoncello J; Aguilar R; Vidal-Alaball J; Moncunill G; Ruiz-Comellas A
    Immunology; 2022 Dec; 167(4):528-543. PubMed ID: 36065677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months.
    Lopera TJ; Chvatal-Medina M; Flórez-Álvarez L; Zapata-Cardona MI; Taborda NA; Rugeles MT; Hernandez JC
    Front Immunol; 2022; 13():879036. PubMed ID: 35585980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.